Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2)
Head-to-head trial showing tirzepatide superior to semaglutide for A1C reduction in Type 2 diabetes.
Video claim watch
Doctors explain how Wegovy and Ozempic work | 60 Minutes
Mainstream 60 Minutes coverage providing clinical and regulatory context for Wegovy/Ozempic.
60 Minutes channel10:00 runtime647K views when checked
Connected research
Compounds discussed
Source check
Primary and peer-reviewed records
Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity (STEP 1)
Phase 3 trial showing semaglutide 2.4 mg weekly achieved mean weight loss of 14.9% at 68 weeks.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
Cardiovascular outcomes trial showing semaglutide reduced major adverse CV events in non-diabetic patients with obesity.
Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6)
Pre-specified CV outcomes trial establishing cardiovascular safety of semaglutide in Type 2 diabetes.
STEP 1: Semaglutide for Obesity: ClinicalTrials.gov
ClinicalTrials.gov registry for STEP 1, the pivotal semaglutide obesity trial.
SELECT: Semaglutide Cardiovascular Outcomes: ClinicalTrials.gov
ClinicalTrials.gov registry for the SELECT cardiovascular outcomes trial of semaglutide.